# CheckMate 205

Source: https://onco.cc/trials/checkmate-205/  
OnCo record `checkmate-205` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Established PD-1 blockade in relapsed Hodgkin lymphoma with ~70% response rates and seeded the frontline nivolumab-AVD idea.

## Summary

CheckMate 205, trial NCT02181738 sponsored by Bristol Myers Squibb and reported in 2016, established PD-1 blockade with nivolumab in relapsed or refractory classical Hodgkin lymphoma after autologous transplant, with responses in about seventy percent of patients, and seeded the frontline nivolumab-AVD idea. Across 243 patients in cohorts A to C the response rate was 69 percent with complete responses in 16 percent and durable progression-free intervals, leading to accelerated approval in May 2016, while cohort D tested nivolumab-AVD in the frontline with very high complete response rates, the basis for SWOG S1826. OnCo links it to Hodgkin lymphoma, nivolumab and the pairing of PD-1 blockade with AVD chemotherapy. Whether PD-1 blockade can replace chemotherapy entirely in some patients is the question its cohort D opened.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT02181738
- Phase: 2
- Setting: Relapsed/refractory classical Hodgkin lymphoma after autologous transplant: nivolumab (cohorts A-C); cohort D nivolumab-AVD frontline
- Sponsor: BMS
- Enrolled: 243
- Result: ORR 69%.
- Outcomes: Objective response rate: Nivolumab 69%

## Sources

- ClinicalTrials.gov NCT02181738: https://clinicaltrials.gov/study/NCT02181738

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- pairings: [PD-1 blockade + AVD chemotherapy](https://onco.cc/pairings/pd1-plus-avd-hodgkin/)
- key papers: [CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up](https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/), [Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial](https://onco.cc/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/)

---
JSON: https://onco.cc/api/v1/entities/checkmate-205.json